NCT05080946暂停1 期
Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 暂停
- 入组人数
- 100
- 试验地点
- 8
- 主要终点
- Change in intratumoral density of immunosuppressive T-regulatory (FOXP3+) cells from diagnostic biopsy to interval debulking surgery
研究概览
简要总结
The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers of immune suppression in the tumor at interval debulking surgery, in women with diagnosed ovarian, fallopian tube, or peritoneal carcinoma
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Participants that are greater than or equal to 18 years of age
- •For U.S. sites, patients can read and understand English or Spanish; for Canadian site, participants can read and understand English or French
- •Histology confirmed, or clinical suspicion of, invasive epithelial ovarian, fallopian tube, or peritoneal carcinoma. Must be grade 2 or 3 or high (where high is defined as grade 2/3). All histologies including serous, endometrioid, clear cell sarcoma, or carcinosarcoma histology is acceptable. Mixed histology also acceptable.
- •Treatment naïve for this cancer diagnosis
- •Planned for neoadjuvant chemotherapy (platinum-based doublet with taxane +/- anti-VEGF antibody) for at least 3 but no more than 5 cycles followed by an interval debulking surgery. [Note: this study evaluates response while on neoadjuvant treatment. The final collection of specimen and questionnaire is at the time of surgery and immediate post-operative state. Therefore, there are no eligibility criteria related to treatment in the adjuvant setting (e.g., intraperitoneal treatment) and adjuvant therapy should proceed as the physician deems appropriate.]
- •Measurable disease as defined by RECIST 1.1, CT scan (with or without contrast) within 12 weeks of study enrollment.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0,1, or 2
- •Able to provide tissue biopsy (core or excisional) sufficient for diagnosis and biomarker analysis, may use outside archival tissue if available.
- •If currently using anti-coagulation medication, no contraindication for temporary stoppage of use during the study based on physician judgement
- •Willing and able to swallow pills without difficulty
- •Un-transfused platelet count > 100,000 cells/μL
- •Willing and able to participate in all required evaluations and procedures in this study protocol (e.g. undergoing treatment, scheduled visits and examinations, serum testing, questionnaires, pill log/diary)
- •Absolute neutrophil count > 1.5 x 109 cells/L
- •Hemoglobin > 9.0 g/dL, may use transfusions and the value can be post-transfusion
- •Estimated creatinine clearance of > 30 mL/min, calculated using the formula Cockcroft-Gault [(140-age) x Mass (kg)/(72 x creatinine mg/dL)] x 0.85 for female
- •No severe hepatic impairment defined as AST or ALT elevation < 2.5 x institutional ULN, unless liver metastasis is present < 5 x ULN
排除标准
- •Definite contraindication for either aspirin use or stopping current aspirin use based on physician's clinical judgment
- •History of vascular event in the last 12 months (e.g., myocardial infarction or unstable angina, stroke, coronary artery angioplasty or stenting, coronary artery bypass graft, relevant [serious or significant] arrhythmias, significant vascular disease, congestive heart failure or vascular interventions).
- •History of hypertensive crisis and/ or uncontrolled HTN, systolic blood pressure > 150 mmHg; diastolic blood pressure > 90mmHg. Participants must have blood pressure < 150/90 mmHg taken in a clinic setting by a medical professional within 2 weeks prior to starting study.
- •Current or history of ulcers which prohibits aspirin consumption, severe hepatic failure, or acute or chronic renal disease where aspirin use is contraindicated
- •History of gastrointestinal or genitourinary bleeding or other bleeding diathesis or coagulopathy within 6 months prior to enrollment of study
- •Uncontrolled erosive esophagitis requiring 2 or more treatments
- •Other cancer diagnosis in the last 3 years other than non-melanoma skin cancer
- •Autoimmune disorder requiring systemic therapy
- •Chronic steroid use defined as 3 weeks in the past year or any length of time in the past 30 days.
- •Other aspirin or NSAID hypersensitivities or contraindications (e.g. allergy)
- •History of bariatric surgery
- •Currently pregnant at the Screening visit or planning on becoming pregnant during the study period
- •Participant is unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with study medication.
- •Metabolism CYP2C9, known G6PD deficient patients
研究组 & 干预措施
Participants Randomized to Placebo
Placebo Comparator
Participants randomized to this arm will receive a daily dose of a placebo (inactive substance)
干预措施: Placebo (Drug)
Participants Randomized to Aspirin
Experimental
Participants randomized to this arm will receive 325mg daily dose aspirin
干预措施: Aspirin 325mg (Drug)
结局指标
主要结局
Change in intratumoral density of immunosuppressive T-regulatory (FOXP3+) cells from diagnostic biopsy to interval debulking surgery
时间窗: Up to 5 months
Change in intratumoral density of immunosuppressive T-regulatory (FOXP3+) cells will be measured by using this formula: (density in the debulking surgery tissue sample - density in the biopsy tissue sample)\*100 / density in the biopsy tissue sample.
Change in intratumoral density of M2 tumor-associated macrophages (CD163+ cells) from diagnostic biopsy to interval debulking surgery
时间窗: Up to 5 Months
Change in intratumoral density of of M2 tumor-associated macrophages (CD163+ cells) will be measured by using this formula: (density in the debulking surgery tissue sample - density in the biopsy tissue sample)\*100 / density in the biopsy tissue sample.
次要结局
- Change in density of tumor COX1(Up to 5 Months)
- Change in blood levels of p-selectin(Up to 84 days)
- Change in blood levels of IL-6(Up to 84 days)
- Change in tumor burden as defined by RECIST 1.1(Up to 5 Months)
- Change in blood levels of CA 125(Up to 84 days)
- Change in density of tumor COX2(Up to 5 Months)
研究者
研究点 (8)
Loading locations...
相似试验
Unknown
1 期
Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck CancerHead and Neck NeoplasmsNCT00982436University of Vermont37
Unknown
2 期
FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric CancerEffects of ChemotherapySurgeryGastric CancerNCT02226380Peking Union Medical College Hospital75
终止
1 期
Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast CancerStages II-III Breast CancerNCT01090128University of Utah27
暂停
1 期
A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric CancerGastric CancerNCT05101616Shanghai Minimally Invasive Surgery Center100
进行中（未招募）
2 期
Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian CancerOvarian CancerNCT05652283Bai-Rong Xia37